阿托伐他汀钙改善慢性硬膜下血肿出血量及神经功能的价值

Value of Atorvastatin Calcium in Improving the Amount of Bleeding and Neurological Function of Chronic Subdural Hematoma

目的观察阿托伐他汀钙改善慢性硬膜下血肿出血量及神经功能的价值。方法选取2019年5月-2023年5月在我院诊治的62例慢性硬膜下血肿患者为研究对象,采用随机数字表法分为对照组和观察组,各组31例。对照组给予常规对症治疗,观察组在对照组基础上联合应用阿托伐他汀钙治疗。比较两组临床疗效、不同时间硬膜下血肿出血量、神经功能缺损(CSS)评分、日常生活活动能力量表(BI)评分、复发率及不良反应发生率。结果观察组治疗总有效率(93.55%)高于对照组(80.65%)(P<0.05);治疗1周、2周后观察组硬膜下血肿出血量均小于对照组(P<0.05);两组CSS评分均低于治疗前,且观察组低于对照组(P<0.05);两组BI评分均高于治疗前,且观察组高于对照组(P<0.05);随访2个月,观察组复发率(3.23%)低于对照组(16.13%)(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论阿托伐他汀钙治疗慢性硬膜下血肿具有显著的效果,可提高治疗效果,减少出血量,改善患者神经功能缺损和日常生活活动能力,降低复发率,且不增加不良反应,值得临床应用。

Objective To observe the value of atorvastatin calcium in improving the amount of bleeding and neurological function of chronic subdural hematoma.Methods A total of 62 patients with chronic subdural hematoma diagnosed and treated in our hospital from May 2019 to May 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 31 patients in each group.The control group was given routine symptomatic treatment,and the observation group was treated with atorvastatin calcium on the basis of the control group.The clinical efficacy,the amount of subdural hematoma at different time,neurological deficit score(CSS),activity of daily living scale score(BI),recurrence rate and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group(93.55%)was higher than that of the control group(80.65%)(P<0.05).After 1 and 2 weeks of treatment,the amount of subdural hematoma in the observation group was less than that in the control group(P<0.05).The CSS score of the two groups was lower than that before treatment,and that of the observation group was lower than that of the control group(P<0.05).The BI score of the two groups was higher than that before treatment,and that of the observation group was higher than that of the control group(P<0.05).After 2 months of follow-up,the recurrence rate of the observation group(3.23%)was lower than that of the control group(16.13%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Atorvastatin calcium has a significant effect in the treatment of chronic subdural hematoma,which can improve the therapeutic effect,reduce the amount of bleeding,improve the neurological deficit and activities of daily living,reduce the recurrence rate,and do not increase the risk of adverse reactions.It is worthy of clinical application.